Open AccessExperimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection
Author(s) -
Juliana M. C. Barbosa,
Yasmin Pedra Rezende,
Tatiana G. Melo,
Gabriel de Oliveira,
Cynthia Machado Cascabulho,
Evelyn Nunes Goulart da Silva Pereira,
Anissa Daliry,
Kelly Salomão
Publication year - 2022
Publication title -
microbiology spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.502
H-Index - 51
ISSN - 2165-0497
DOI - 10.1128/spectrum.01852-21
Subject(s) - benznidazole , chagas disease , trypanosoma cruzi , nifurtimox , parasitemia , medicine , pharmacology , amiodarone , combination therapy , cardiomyopathy , heart failure , immunology , malaria , parasite hosting , plasmodium falciparum , world wide web , computer science , atrial fibrillation
Chagas disease affects approximately 6 to 7 million people worldwide, with cardiomyopathy being the clinical manifestation that most commonly leads to patient death. The etiological treatment of Chagas disease is limited to drugs (benznidazole and nifurtimox) with relatively high toxicity and therapeutic failures.